Wire · opportunities
Alnylam Pharmaceuticals (ALNY) Wins FDA Approval in Myasthenia Gravis With Seventh RNAi Drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
Alnylam Pharmaceuticals and Regeneron won FDA approval for Livsayis, the first RNAi-based therapy for generalized myasthenia gravis, marking Alnylam's seventh FDA-approved RNA interference drug in around nine years.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new FDA-cleared RNA interference therapy for a rare neuromuscular disease opening a revenue stream beyond previous drug franchises. Watch Regeneron's sales reports closely for early signs of market takeoff and royalty growth.
◆ Coverage
1 source · 21 Nov 2026
◆ Related on Wire
◆ Topics